NCT07465757 2026-03-12
ALISCA-Lung2
Puma Biotechnology, Inc.
Phase 2 Not yet recruiting
Clinical Trials
4 trialsNCT06095505 2026-02-17
ALISCA-Lung1
Puma Biotechnology, Inc.
Phase 2 Recruiting
NCT02293005 2022-10-04
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02038647 2018-12-27
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Takeda
Phase 2 Completed